98%
921
2 minutes
20
Nanomotor chassis constructed from biological precursors and powered by biocatalytic transformations can offer important applications in the future, specifically in emergent biomedical techniques. Herein, cross β amyloid peptide-based nanomotors (amylobots) were prepared from short amyloid peptides. Owing to their remarkable binding capabilities, these soft constructs are able to host dedicated enzymes to catalyze orthogonal substrates for motility and navigation. Urease helps in powering the self-diffusiophoretic motion, while cytochrome C helps in providing navigation control. Supported by the simulation model, the design principle demonstrates the utilization of two distinct transport behaviours for two different types of enzymes, firstly enhanced diffusivity of urease with increasing fuel (urea) concentration and secondly, chemotactic motility of cytochrome C towards its substrate (pyrogallol). Dual catalytic engines allow the amylobots to be utilized for enhanced catalysis in organic solvent and can thus complement the technological applications of enzymes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516904 | PMC |
http://dx.doi.org/10.1038/s41467-023-41301-x | DOI Listing |
Alzheimers Dement
September 2025
Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, South Korea.
Introduction: We developed and validated age-related amyloid beta (Aβ) positron emission tomography (PET) trajectories using a statistical model in cognitively unimpaired (CU) individuals.
Methods: We analyzed 849 CU Korean and 521 CU non-Hispanic White (NHW) participants after propensity score matching. Aβ PET trajectories were modeled using the generalized additive model for location, scale, and shape (GAMLSS) based on baseline data and validated with longitudinal data.
Brain Commun
September 2025
Alzheimer's Disease Cooperative Study (ADCS), Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.
Several studies implicate circadian rhythm disturbances in Alzheimer's disease. However, very little is known about how circadian rhythms are associated with Alzheimer's pathological biomarkers in older adults at early stages of the disease, and how these relationships map onto cognition. This cross-sectional study used 24-h accelerometry data to investigate the relationships between circadian rhythms, amyloid-β (Aβ), tau, and cognition in 68 older adults with objective early cognitive impairment.
View Article and Find Full Text PDFAlzheimers Dement
September 2025
Research Service, VA San Diego Healthcare System, San Diego, California, USA.
Introduction: Among individuals who are amyloid biomarker-positive or apolipoprotein E (APOE) ε4 carriers, arterial stiffness reflected by higher pulse wave velocity (PWV) has been associated with lower cognition cross-sectionally. Less is known about longitudinal associations.
Methods: The sample included 152 older adults without dementia.
J Alzheimers Dis Rep
September 2025
Communication Sciences and Disorders, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Background: The presence of the apolipoprotein E4 () allele and periodontal disease are independently correlated with higher levels of amyloid-β and inflammation in the brain, worse cognition, and Alzheimer's disease.
Objective: To assess whether the presence of the allele modifies the relationship between IgG antibodies against periodontal microorganisms and cognitive function in older adults participating in the NHANES III study.
Methods: This cross-sectional analysis was conducted among participants of the third National Health and Nutrition Examination Survey (NHANES III) (1988 to 1994), aged 60 years and older, with measurements of IgG antibodies against 19 periodontal microorganisms and alleles (N = 1644).
Biomed Pharmacother
September 2025
Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, University of Seville, Spain; Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Seville, 41013, Spain. Electronic address:
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairment, synaptic dysfunction, and neuronal loss. Neuroinflammation, driven by the activation of microglia and astrocytes, is a key contributor to AD pathology, amplifying oxidative stress and amyloid-β toxicity. Modulation of neuroinflammatory pathways thus represents a promising therapeutic strategy.
View Article and Find Full Text PDF